← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
GI-6207 (GI-6207)
ImmunityBio, Inc.·Melanoma
15 trials
Overview
Program
GI-6207
Overview
Company
ImmunityBio, Inc.
Overview
Modality
CGT
Overview
Target
Melanoma
Overview
Indication
Melanoma
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Pembrolizumab in recurrent or metastatic medullary thyroid cancer.. It has been hypothesized that sequencing antigen-directed immunotherapy with immune checkpoint inhibitors could prime a tumor for immune response to immune checkpoint inhibitors. This study (NCT03072160) was designed to evaluate two cohorts of patients with medullary thyroid cancer, a cancer that is not known to have therapeutic r…
Clinical
Safety signal
Pembrolizumab in recurrent or metastatic medullary thyroid cancer.. It has been hypothesized that sequencing antigen-directed immunotherapy with immune checkpoint inhibitors could prime a tumor for immune response to immune checkpoint inhibitors. This study (NCT03072160) was designed to evaluate two cohorts of patients with medullary thyroid cancer, a cancer that is not known to have therapeutic r…
Clinical
Selected reported efficacy
ORR 6%
Clinical
Reported ORR
6%
Clinical
Result source
ClinicalTrials.gov NCT03387085
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT03387085